The increase of hematopoiesis turbulence by the last years of
life is typical for patients with metastatic
non-small cell lung cancer (NSCC) that leads to the
risk of their overtreatment. The hematopoietic
stem cells (HSC) and mitotic index (MI) in the blood'
lymphocytes of thirty-five patients were
measured by flow cytometry before conventional
cytotoxic therapy and then compared with their life
span after treatment. The plot of the individual
product (CD133+HSC × MI) versus CD34+HSC
revealed the prognostic properties during the survival
period (range 0.3–124 months). Discrimination
of patients with an expected survival shorter than 12
months was possible based on the positions of
individual points on the plot, with a sensitivity and
specificity of ~100 each and a diagnostic odds ratio
of 1250. The ratio of lymphoproliferative potency and
the cumulative dose of systemic hematosuppressive therapy determines the
prevalence of cancer growth suppression or an adverse effect on the physiological systems responsible for maintaining the
viability of the host organism. The higher potency
associates with a longer duration during which the therapy may be successful,
and vice versa.The proposed competitive
mechanism for tumor control in the host assumes the partial
distraction
the trophic circulating cells from tumor to offside tissue priorities,
like reparation of a
multitude of hematopoietic and other non-malignant
cells injured sub-lethally. The stronger the trophic
influence of lymphopoiesis on the tissues of the cancer
host is, the higher the probability and benefit
of this therapeutic mechanism will be. The definition
an activation of anticancer immunity is better to
replace on definition a reduction of tumor
morphogenesis.The main task for future investigations is the
phases of cyclic lymphopoiesis, which are optimal for
the induction of regenerative processes outside
the tumor in surrounding tissues.
Author
(s) Details
Aleksey N. Shoutko
Laboratory for Improvement of the Radiation Treatment Methods, Federal
Research Center for Radiology and Surgical Technologies, Saint-Petersburg,
Russia.
Victor F. Mus
Group for Lung Cancer Treatment, Federal Research Center for Radiology and
Surgical Technologies, Saint-Petersburg, Russia.
Dmitry N. Maystrenko
Department of Vascular Surgery, Federal Research Center for Radiology and
Surgical Technologies, Saint-Petersburg, Russia.
View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/270
No comments:
Post a Comment